Advertisement

Drugs

, Volume 72, Issue 11, pp 1535–1541 | Cite as

Vismodegib

In Locally Advanced or Metastatic Basal Cell Carcinoma
  • Gillian M. Keating
Adis Drug Profile

Abstract

Vismodegib is the first Hedgehog pathway inhibitor to be approved in the US, where it is indicated for the treatment of adults with metastatic basal cell carcinoma (BCC), or with locally advanced BCC that has recurred following surgery or who are not candidates for surgery, and who are not candidates for radiation. Vismodegib selectively and potently inhibits the Hedgehog signalling pathway by binding to Smoothened, thereby inhibiting the activation of Hedgehog target genes.

Oral vismodegib was effective in the treatment of patients with locally advanced (n = 63) or metastatic (n= 33) BCC, according to the results of an ongoing, noncomparative, multinational, pivotal, phase II trial (ERIVANCE BCC). In this trial (using a clinical cutoff date of 26 November 2010), the independent review facility overall response rate was 42.9% in patients with locally advanced BCC and 30.3% in patients with metastatic BCC. In both patients with locally advanced BCC and those with metastatic BCC, the median duration of response was 7.6 months and median progression-free survival was 9.5 months.

Oral vismodegib had an acceptable tolerability profile in patients with advanced BCC.

Keywords

Medulloblastoma Basal Cell Carcinoma Overall Response Rate Vismodegib Hedgehog Signalling Pathway 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): basal cell and squamous cell skin cancers (version 2.2012) [online]. Available from URL: http://www.nccn.org/professionals/physician_gls/pdf/nmsc.pdf [Accessed 2012 Mar 29]
  2. 2.
    Weinstock MA, Still JM. Assessing current treatment options for patients with severe/advanced basal cell carcinoma. Semin Cutan Med Surg 2011 Dec; 30(4 Suppl.): S10–3PubMedCrossRefGoogle Scholar
  3. 3.
    Harris LG, Samant RS, Shevde LA. Hedgehog signaling: networking to nurture a promalignant tumor micro-environment. Mol Cancer Res 2011 Sep; 9(9): 1165–74PubMedCrossRefGoogle Scholar
  4. 4.
    LoRusso PM, Rudin CM, Reddy JC, et al. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res 2011 Apr 15; 17(8): 2502–11PubMedCrossRefGoogle Scholar
  5. 5.
    F. Hoffmann-La Roche Ltd. FDA approves Erivedge (vismodegib) capsule, the first medicine for adults with advanced basal cell carcinoma [media release; online]. Available from URL: http://www.roche.com/media/media_releases/med-cor-2012-01-30.htm [Accessed 2012 Apr 4]
  6. 6.
    Genentech, Inc. Erivedge™ (vismodegib) capsule for oral use: US prescribing information [online]. Available from URL: http://www.gene.com/gene/products/information/erivedge/pdf/erivedge_prescribing.pdf [Accessed 2012 Mar 28]
  7. 7.
    Von Hoff DD, LoRusso PM, Rudin CM, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 2009 Sep 17; 361(12): 1164–72CrossRefGoogle Scholar
  8. 8.
    Graham RA, Lum BL, Cheeti S, et al. Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein binding. Clin Cancer Res 2011 Apr 15; 17(8): 2512–20PubMedCrossRefGoogle Scholar
  9. 9.
    Robarge KD, Brunton SA, Castanedo GM, et al. GDC-0449: a potent inhibitor of the hedgehog pathway. Bioorg Med Chem Lett 2009 Oct 1; 19(19): 5576–81PubMedCrossRefGoogle Scholar
  10. 10.
    Yauch RL, Gould SE, Scales SJ, et al. A paracrine requirement for hedgehog signalling in cancer. Nature 2008 Sep 18; 455(7211): 406–10PubMedCrossRefGoogle Scholar
  11. 11.
    Wong H, Alicke B, West KA, et al. Pharmacokinetic-pharmacodynamic analysis of vismodegib in preclinical models of mutational and ligand-dependent hedgehog pathway activation. Clin Cancer Res 2011 Jul 15; 17(14): 4682–92PubMedCrossRefGoogle Scholar
  12. 12.
    Giannetti AM, Wong H, Dijkgraaf GJP, et al. Identification, characterization, and implications of species-dependent plasma protein binding for the oral Hedgehog pathway inhibitor vismodegib (GDC-0449). J Med Chem 2011 Apr 28; 54(8): 2592–601PubMedCrossRefGoogle Scholar
  13. 13.
    Wong H, Chen JZ, Chou et al. Preclinical assessment of the absorption, distribution, metabolism and excretion of GDC-0449 (2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide), an orally bioavailable systemic Hedgehog signalling pathway inhibitor. Xenobiotica 2009 Nov; 39(11): 850–61PubMedCrossRefGoogle Scholar
  14. 14.
    LoRusso PM, Jimeno A, Dy G, et al. Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors. Clin Cancer Res 2011 Sep 1; 17(17): 5774–82PubMedCrossRefGoogle Scholar
  15. 15.
    Rudin CM, Hann CL, Laterra J, et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med 2009 Sep 17; 361(12): 1173–8PubMedCrossRefGoogle Scholar
  16. 16.
    Graham RA, Hop CECA, Borin MT, et al. Single- and multiple-dose intravenous and oral pharmacokinetics of the Hedgehog pathway inhibitor vismodegib in healthy female subjects. Br J Clin Pharmacol. Epub 2012 Mar 27Google Scholar
  17. 17.
    Sharma M, Kang SP, Karrison T, et al. Evaluation of food effect on pharmacokinetics (PK) of GDC-0449 (G) in advanced solid tumor patients [abstract no. e1 3106]. 48th Annual Meeting of the American Society of Clinical Oncology; 2012 Jun 1–5; Chicago (IL)Google Scholar
  18. 18.
    Graham RA, Lum BL, Morrison G, et al. A single dose mass balance study of the Hedgehog pathway inhibitor vismodegib (GDC-0449) in humans using accelerator mass spectrometry. Drug Metab Dispos 2011 Aug; 39(8): 1460–7PubMedCrossRefGoogle Scholar
  19. 19.
    Lum BL, Morrison GE, Chang I, et al. A phase I, open-label mass balance study of the hedgehog pathway inhibitor (HPI) GDC-0449 in healthy female subjects of non-childbearing potential [abstract no. 2558]. 46th Annual Meeting of the American Society of Clinical Oncology; 2010 Jun 4–8; Chicago (IL)Google Scholar
  20. 20.
    LoRusso PM, Piha-Paul SA, Colevas AD, et al. Pharmacokinetic assessment of drugdrug interaction potential when rosiglitazone or combined oral contraceptive is coadministered with vismodegib in patients with locally advanced or metastatic solid tumors [abstract]. 2011 AACR-NCI-EORTC International Conference: Molecular Targets and Cancer; 2011 Nov 12–16; San Francisco (CA)Google Scholar
  21. 21.
    Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 2012 Jun 7; 366(23): 2171–9PubMedCrossRefGoogle Scholar
  22. 22.
    Sekulic A, Migden MR, Oro AE, et al. Effiacy and safety of the Hedgehog pathway inhibitor vismodegib in patients with advanced basal cell carcinoma (BCC): ERIVANCE BCC study update [abstract no. 8579]. 48th Annual Meeting of the American Society of Clinical Oncology; 2012 Jun 1–5; Chicago (IL)Google Scholar

Copyright information

© Springer International Publishing AG 2012

Authors and Affiliations

  1. 1.AdisMairangi Bay, North Shore 0754, AucklandNew Zealand

Personalised recommendations